Pierre Fabre and its partner Array BioPharma announce interim analysis results from the BEACON CRC Trial of encorafenib + binimetinib + cetuximab for the treatment of BRAFV600E-mutant metastatic colorectal cancer | Business Wire
Pharmaceutical Laboratory : Recruitment | Pierre Fabre
TCT-ASTCT-CIBMTR 2022: Multicenter, Open-Label, Phase 3 (P3) Study of Tabelecleucel (Tab-cel) for Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplant (HCT) Recipients with Epstein–Barr Virus-Driven Post Transplant Lymphoproliferative Disease ...
STUDY: L00070 IN 309 F0
Articles about Atara Biotherapeutics, Inc. | page 2
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Upcoming events – Beacons of hope for Array and Proteon | Evaluate
Urovant's Gemtesa (vibegron) Receives the US FDA's Approval for Overactive Bladder
Pierre Fabre pens oncology pact with atomic energy spinout | Fierce Biotech
Moving on from Novartis, Array inks a $455M oncology deal with Pierre Fabre | Fierce Biotech
Pierre Fabre and its partner Array BioPharma announce interim analysis results from the BEACON CRC Trial of encorafenib + binimetinib + cetuximab for the treatment of BRAFV600E-mutant metastatic colorectal cancer | Business Wire
Pierre Fabre Receives European Approval for BRAFTOVI® (encorafenib) in Combination With Cetuximab for the Treatment of Adult Patients With BRAFV600E-Mutant Metastatic Colorectal Cancer | Business Wire
STUDY: L00070 IN 309 F0
ESMO-BC 2022: Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+ / HR+ early breast cancer (eBC)
Pierre Fabre and its partner Array BioPharma announce interim analysis results from the BEACON CRC Trial of encorafenib + binimetinib + cetuximab for the treatment of BRAFV600E-mutant metastatic colorectal cancer | Business Wire
Jairo Pardey - Chief Executive Officer, Hong Kong & Macau - Pierre Fabre Group | LinkedIn
Puma regains China rights to Nerlynx and amends deal with Fabre
Trust & Expectations – Helping Philippe Jardin become VP at Pierre Fabre - Boyd & Moore Executive Search
PharmaShots Interview: Pierre Fabre' Roberta Valenti Shares Insights on Nerlynx (neratinib) for the Treatment of HER2 Early Breast Cancer
Adjuvant pembrolizumab extends DFS in resected early-stage non-small cell lung cancer
Untitled
Scorpion & Pierre Fabre Agreement for Lung Cancer Treatment
